Dividends & Buybacks ·
Moleculin Biotech approves 1-for-20 reverse stock split effective Oct. 20
MBRXMoleculin Biotech, Inc.
Moleculin Biotech's board approved a one-for-twenty (1:20) reverse stock split of its common stock, following shareholder authorization at the annual meeting on October 9, 2026. The amendment to the certificate of incorporation was filed with the Delaware Secretary of State and will become effective at 12:01 a.m. Eastern Time on October 20, 2026. Trading on the Nasdaq Capital Market will resume on a post-split basis under ticker MBRX with a new CUSIP number. Outstanding shares will decrease from approximately 20.9 million to roughly 1.05 million, while authorized shares remain at 500 million. Fractional shares will be cashed out based on the average closing price over the preceding five trading days. Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing therapeutic candidates for hard-to-treat tumors and viruses.